Levonorgestrel
Highest phase reached
Approved
Drug type
Small molecule
First approval year
1982
- First approval year
- 1982
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Small molecule
- Drug name
- Levonorgestrel
- Molecular weight
- 312.45
- Structure (SMILES)
- C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@@]21CC
- athentia next
- Athentia next
- emerres
- Emerres
- emerres una
- Emerres una
- ezinelle
- Ezinelle
- fallback solo
- Fallback solo
- her style
- Her style
- isteranda
- Isteranda
- jadelle
- Jadelle
- jaydess
- Jaydess
- kyleena
- Kyleena
- levonelle
- Levonelle
- levonelle 2
- levonelle one step
- Levonelle one step
And 97 more, listed on the interactive page.
- (-)-13-ETHYL-17-HYDROXY-18,19-DINOR-17.ALPHA.-PREGN-4-EN-20-YN-3-ONE
- 13 ethyl 17 hydroxy 18 19 dinor 17 alpha pregn 4 en 20 yn 3 one
- 150 mcg levonorgestrel 30 mcg ethinyl estradiol
- 18 19 dinorpregn 4 en 20 yn 3 one 13 ethyl 17 hydroxy 17 alpha
- 18,19-DINORPREGN-4-EN-20-YN-3-ONE, 13-ETHYL-17-HYDROXY-, (17.ALPHA.)-(-)-
- afirmelle component levonorgestrel
- AFIRMELLE COMPONENT LEVONORGESTREL
- alesse component levonorgestrel
- ALESSE COMPONENT LEVONORGESTREL
- altavera component levonorgestrel
- ALTAVERA COMPONENT LEVONORGESTREL
- aviane component levonorgestrel
- AVIANE COMPONENT LEVONORGESTREL
- bay86 5028
- BAY86-5028
- ChloraPrep One Step
- ChloraPrep One-Step
- climara pro component levonorgestrel
- CLIMARA PRO COMPONENT LEVONORGESTREL
- elifemme component levonorgestrel
- ELIFEMME COMPONENT LEVONORGESTREL
- enpresse component levonorgestrel
- ENPRESSE COMPONENT LEVONORGESTREL
- implant with levonorgestrel
- IMPLANT WITH LEVONORGESTREL
And 115 more, listed on the interactive page.
- CAS registry numbers
- 797-63-7
- ChEMBL ID
- CHEMBL1389
- InChIKey
- WWYNJERNGUHSAO-XUDSTZEESA-N
- PubChem compound IDs
- 13109
- RxNorm IDs (RxCUI)
- 6373
- FDA ingredient codes (UNII)
- 5W7SIA7YZW
- G03AC03
- G03AD01
Sources for recorded values
- Applicant
- BAYER HLTHCARE
- Approval date
- 6 Dec 2000
- Application number
- NDA021225
- Patents
- 12
- Designations
- 0
- Earliest recorded loss of exclusivity
- 7 Sept 2040
- First in class
- No
- Fast track
- No
- Breakthrough designation
- No
- Orphan designation
- No
- Priority review
- No
- Orphan exclusivity
- No
- Accelerated approval
- No
- Availability
- Over the counter
- Pharmacology name
- levonorgestrel
- Type
- Synthetic organic
- Drug name stem
- -estr-; -gest-
- Approval recorded by Guide to Pharmacology
- Yes
Administration routes
- Oral
- Parenteral
- topical
- Action
- Agonist
- Action type
- Agonist
- Target
- Progesterone receptor
- Gene symbol
- PGR
- Protein identifier
- P06401
- Primary target
- Yes
- Mechanism
- Progesterone receptor agonist
- Action type
- Agonist
- Target
- Progesterone receptor
- Protein identifier
- P06401
Open Targets mechanisms
- Mechanism
- Progesterone receptor agonist
- Action type
- Agonist
- Target
- Progesterone receptor
DrugCentral mechanisms
- Action type
- Agonist
- Gene symbol
- PGR
- Protein identifier
- P06401
- Organism
- Homo sapiens
- Target development level
- Clinical
- Condition
- Leukemia, Lymphocytic, Chronic, B-Cell
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000095
- Subject identifier
- D015451
- Condition
- HIV Infections
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000180
- Subject identifier
- D015658
- Condition
- Diabetes Mellitus
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000400
- Subject identifier
- D003920
- Condition
- HIV Infections
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000764
- Subject identifier
- D015658
- Condition
- Endometriosis
- Highest recorded phase
- 3
- Condition identifier
- EFO:0001065
- Subject identifier
- D004715
- Condition
- Ovarian Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:0001075
- Subject identifier
- D010051
- Condition
- Pregnancy
- Highest recorded phase
- 2
- Condition identifier
- EFO:0002950
- Subject identifier
- D011247
- Condition
- Pain
- Highest recorded phase
- 2
- Condition identifier
- EFO:0003843
- Subject identifier
- D010146
- Condition
- Hepatitis C, Chronic
- Highest recorded phase
- 1
- Condition identifier
- EFO:0004220
- Subject identifier
- D019698
- Condition
- Hepatitis B, Chronic
- Highest recorded phase
- 1
- Condition identifier
- EFO:0004239
- Subject identifier
- D019694
- Condition
- Non-alcoholic Fatty Liver Disease
- Highest recorded phase
- 1
- Condition identifier
- EFO:1001249
- Subject identifier
- D065626
- Condition
- Endometrial Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:1001512
- Subject identifier
- D016889
- Condition
- Adenomyosis
- Highest recorded phase
- 2
- Condition identifier
- EFO:1001757
- Subject identifier
- D062788
- Condition
- Menorrhagia
- Highest recorded phase
- 4
- Condition identifier
- HP:0000132
- Subject identifier
- D008595
- Condition
- Bone Diseases, Metabolic
- Highest recorded phase
- 3
- Condition identifier
- HP:0000938
- Subject identifier
- D001851
- Condition
- Dysmenorrhea
- Highest recorded phase
- 3
- Condition identifier
- HP:0100607
- Subject identifier
- D004412
- Condition
- Neoplasms
- Highest recorded phase
- 1
- Condition identifier
- MONDO:0004992
- Subject identifier
- D009369
- Condition
- Diabetes Mellitus, Type 2
- Highest recorded phase
- 1
- Condition identifier
- MONDO:0005148
- Subject identifier
- D003924
- Condition
- Migraine Disorders
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0005277
- Subject identifier
- D008881
- Condition
- Anorexia Nervosa
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0005351
- Subject identifier
- D000856
- Condition
- Hemorrhage
- Highest recorded phase
- 3
- Condition identifier
- MP:0001914
- Subject identifier
- D006470
- Condition identifier
- EFO_0000095
- Highest recorded phase
- 1
- Condition identifier
- EFO_0000400
- Highest recorded phase
- 1
- Condition identifier
- EFO_0000545
- Condition identifier
- EFO_0000764
- Highest recorded phase
- 1
- Condition identifier
- EFO_0001065
- Condition identifier
- EFO_0001073
- Condition identifier
- EFO_0001075
- Highest recorded phase
- 2
- Condition identifier
- EFO_0002950
- Condition identifier
- EFO_0002950
- Highest recorded phase
- 2
- Condition identifier
- EFO_0003882
- Condition identifier
- EFO_0005279
- Condition identifier
- EFO_0009520
- Condition identifier
- EFO_0009520
- Highest recorded phase
- 4
- Condition identifier
- EFO_1000235
- Highest recorded phase
- 2
- Condition identifier
- EFO_1000237
- Condition identifier
- GO_0030728
- Highest recorded phase
- 2
- Condition identifier
- HP_0000132
- Condition identifier
- HP_0000132
- Highest recorded phase
- 4
- Condition identifier
- HP_0000789
- Condition identifier
- HP_0000855
- Condition identifier
- HP_0000938
- Highest recorded phase
- 3
- Condition identifier
- HP_0001007
- Highest recorded phase
- 2
- Condition identifier
- HP_0001513
- Highest recorded phase
- 3
- Condition identifier
- HP_0001891
- Condition identifier
- HP_0002018
- Highest recorded phase
- 2
And 28 more, listed on the interactive page.
- Event
- abdominal pain
- Reports
- 2,616
- Reporting signal score
- 1,958.2
- Event
- abdominal pain lower
- Reports
- 3,135
- Reporting signal score
- 9,437.71
- Event
- acne
- Reports
- 471
- Reporting signal score
- 568.07
- Event
- amenorrhoea
- Reports
- 990
- Reporting signal score
- 2,458.96
- Event
- anxiety
- Reports
- 1,501
- Reporting signal score
- 798.355
- Event
- breast cancer female
- Reports
- 291
- Reporting signal score
- 590.548
- Event
- breast pain
- Reports
- 259
- Reporting signal score
- 441.457
- Event
- coital bleeding
- Reports
- 202
- Reporting signal score
- 671.769
- Event
- contraindicated device used
- Reports
- 126
- Reporting signal score
- 481.02
- Event
- depression
- Reports
- 1,535
- Reporting signal score
- 858.633
- Event
- device misuse
- Reports
- 217
- Reporting signal score
- 768.645
- Event
- device physical property issue
- Reports
- 220
- Reporting signal score
- 479.352
- Event
- device use issue
- Reports
- 760
- Reporting signal score
- 2,300.04
- Event
- diarrhoea
- Reports
- 105
- Reporting signal score
- 1,041.22
- Event
- drug hypersensitivity
- Reports
- 20
- Reporting signal score
- 585.325
- Event
- dysmenorrhoea
- Reports
- 343
- Reporting signal score
- 795.683
- Event
- dyspareunia
- Reports
- 629
- Reporting signal score
- 2,032.73
- Event
- dyspnoea
- Reports
- 213
- Reporting signal score
- 653.358
- Event
- ectopic pregnancy
- Reports
- 231
- Reporting signal score
- 516.162
- Event
- ectopic pregnancy with intrauterine device
- Reports
- 198
- Reporting signal score
- 758.274
- Event
- emotional distress
- Reports
- 1,026
- Reporting signal score
- 2,169.67
- Event
- expired device used
- Reports
- 295
- Reporting signal score
- 1,043.33
- Event
- fall
- Reports
- 36
- Reporting signal score
- 608.091
- Event
- genital haemorrhage
- Reports
- 3,828
- Reporting signal score
- 14,516
- Event
- haemorrhage in pregnancy
- Reports
- 217
- Reporting signal score
- 671.503
And 36 more, listed on the interactive page.
- NCT00117260
- NCT00196313
- NCT00196365
- NCT00909857
- NCT00254800
- NCT01508858
- NCT00360490
- NCT00393198
- NCT00966264
- NCT01165307
- NCT03642210
- NCT00445887
- NCT00482963
- NCT01789879
- NCT02159131
- NCT02722421
- NCT00781456
- NCT04007874
- NCT01125488
- NCT02203331
- NCT02599077
- NCT01343771
- NCT01570244
- NCT01601366
- NCT01695902
And 10 more, listed on the interactive page.
- Hydrogen bond acceptors
- 2
- Hydrogen bond donors
- 1
- Polar surface area
- 37.3
- Calculated partition coefficient (ALogP)
- 3.88
- Calculated partition coefficient (XLogP)
- 3.3
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 1
- Heavy atoms
- 23
- Molecular formula
- C21H28O2
- Monoisotopic mass
- 312.208930132
- Natural product
- Yes
- 0023-5858
- 0480-3472
- 40032-622
- 50419-422
- 50419-423
- 50419-424
- 50419-491
- 50742-659
- 68462-637
- 71671-100
- Recorded assays
- 3,285
- Active assays
- 151
- Confirmatory
- Other
- Screening
- Summary
- Contraceptive Agents, Hormonal
- Contraceptive Agents, Female
- Contraceptives, Oral, Synthetic
Oral bioavailability
- Median
- 87
- Mean
- 87
- Minimum
- 87
- Maximum
- 87
- Unit
- %
- Assays
- 1
- Standard deviation
- 0
- Summary method
- median
- Censored results excluded
- 0
- Other units excluded
- 0
- Unknown units excluded
- 0
Measurement types
- F
Related records
Trials (212)
- 'Levonorgestrel IUD Insertion After D&E Procedure
- "E4/DRSP Endocrine Function, Metabolic Control and Hemostasis Study"
- A Cross-sectional, Observational Multicenter Study to Assess the Reasons for Choosing the 3-year Hormonal IUD and Level of IUDs Knowledge Among Women Aged 18 to 29 Years
- A Drug Interaction Study of BIIB074 and an Oral Contraceptive Regimen
- A Drug-Drug Interaction Study of MK 8527 With a Combined Oral Contraceptive (LNG/EE)
- A Drug-drug Interaction Trial in Healthy Female Participants to Investigate the Effect of Aprocitentan on Combined Hormonal Contraceptives
- A Multi-center, Open-label, Randomized, Parallel Group Study to Evaluate Pharmacokinetic Profile, Effects on the Mechanisms of Contraceptive Efficacy and Safety of Two Progestin-only Patches Containing Different Doses of Levonorgestrel (LNG)
- A Multicenter Study to Evaluate the Effects of a 91-Day Extended Cycle Oral Contraceptive on Hemostatic Parameters in Healthy Women
- A Multicenter Study to Evaluate the Effects of a 91-day Oral Contraceptive on Bone Mineral Density in Adolescent Females
- A Multicenter Study to Evaluate the Efficacy of a 91-Day Extended Cycle Oral Contraceptive for Menstrually-Related Migraine Headaches
- A Multicenter Study to Evaluate the Safety of Seasonique, an Oral Contraceptive.
- A Pharmacokinetic Evaluation of Levonorgestrel Implant and Antiretroviral Therapy
- A Phase 1 Study to Assess the Effect of ABBV-722 on Ethinyl Estradiol and Levonorgestrel Drug Levels in Healthy Adult Female Participants
- A Phase I Study to Evaluate the PK and PD of a Single Injection of Levonorgestrel Butanoate for Female Contraception
- A Pilot Study of Early Postpartum Intrauterine Contraception
- A Pilot Study on Fertility Conservative Treatment of Atypical Endometrial Hyperplasia in Singapore
- A Postmarketing Open-Label Study to Assess Residual Levonorgestrel (LNG) and Ethinyl Estradiol (EE) Content of TWIRLA® (Levonorgestrel and Ethinyl Estradiol) Transdermal System
- A Research Study Looking at How the Compound NNC0194-0499 Works With Birth Control Pills in Women Not Able to Bear Children.
- A Research Study Looking at How the Compound NNC0487-0111 Works With Birth Control Pills and Affects Emptying of the Stomach in Women Not Able to Become Pregnant
- A Research Study Looking Into the Effect of NNC0519-0130 on Blood Levels of a Birth Control Pill and Emptying of the Stomach in Women After Menopause
In development for (17)
- Adenomyosis Phase 2
- Anorexia nervosa Phase 3
- B-cell chronic lymphocytic leukemia Phase 1
- Cancer Phase 1
- Chronic hepatitis B virus infection Phase 1
- Chronic hepatitis C virus infection Phase 1
- Diabetes mellitus Phase 1
- Dysmenorrhea Phase 3
- Endometrial carcinoma Phase 2
- Endometriosis Phase 3
- HIV infectious disease Phase 2
- Metabolic bone disorder Phase 3
- Metabolic dysfunction-associated steatohepatitis Phase 1
- Migraine disorder Phase 3
- Ovarian carcinoma Phase 2
- Premenstrual tension Phase 3
- Type 2 diabetes mellitus Phase 1
Other linked conditions (5)
- Endometrial polyp
- Infertility disorder
- Obesity disorder
- Osteoporosis
- Temporomandibular joint disorder
Targets (1)
- PGR Progesterone receptor agonist